UNITY Biotechnology Inc
Change company Symbol lookup
Select an option...
UBX UNITY Biotechnology Inc
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
Go

Health Care : Biotechnology |
Company profile

Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.

Postmarket

Last Trade
Delayed
$3.42
-0.02 (-0.58%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.44
Day's Change
-0.03 (-0.86%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
3.49
Day's Low
3.35
Volume
(Light)
Volume:
464,841

10-day average volume:
1,179,541
464,841

Company Profile

Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.60x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2020
Current Month
3.5M
Previous Month
3.6M
Percent of Float
8.36%
Days to Cover
3.7308 Days

Share Information

UBX is in a share class of common stock
Float
42.5M
Shares Outstanding
52.0M
Institutions Holding Shares
111
71.96%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Keith R. LeonardChmn.
  • Nathaniel E. DavidPres.
  • Anirvan GhoshCEO
  • Lynne SullivanCFO
  • Alexander AzoyCAO

Address

Insider Trading

During the most recent quarter, 3K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.